L6M-25553-24605
1 vaccination
1 coded response
8 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 830 / WY
- Registered
- 2021-03-16
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-16
Registered in v-safe
-
2021-03-16
Dose 1 — Pfizer-BioNTech
- 2021-03-16
- 2021-03-17
- 2021-03-18
- 2021-03-19
- 2021-03-20
- 2021-03-21
- 2021-03-22
-
2021-09-14
Survey response — 6 months, dose 1MedDRA: Ageusia, Anosmia, Dyspnoea, Fatigue, Headache, Oesophageal achalasia, Productive cough — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Shortness of breath, headache, aches, productive cough, loss of taste and sense of smell, fatigue.MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-16 | Pfizer-BioNTech |
Free text
Release 9 — 6 months, dose 1
Symptoms: Shortness of breath, headache, aches, productive cough, loss of taste and sense of smell, fatigue.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Oesophageal achalasia | · | · | ✓ |
| SD | Productive cough | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release